Popular Articles
Benefits Of Grapefruit

Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
generic viagra online
A "Fresh Start" To Summer; New Program Offers Personalized Physician-assisted Approach To Losing Weight
Perhaps the only thing harder than sticking to a weight loss plan is starting a new one after yet another failed diet attempt. Physicians Sharon Herring and Stephanie Ward recognize such "diet fatigue" in their patients and their own families. Now, they"re offering a "fresh start" to the diet-weary.
News of the day
News From The Journals Of The American Society For Microbiology
"Single-Shot" Vaccines May Protect Against H5N1 Influenza Virus
Diagnostics

Identification Of One Gene That Contributes To Breast Cancer's Aggressive Behavior

Aggressive forms of cancer are often driven by the abnormal over-expression of cancer-promoting genes, also known as oncogenes. Studies at the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR) of Singapore, have identified a gene, known as RCP (or RAB11FIP1), that is frequently amplified and over-expressed in breast cancer and functionally contributes to aggressive breast cancer behaviour. The research findings are published in the July 20th online issue of Journal of Clinical Investigation (JCI). The GIS team, led by Lance Miller, Ph.D., and Bing Lim, Ph.D., initially discovered that RCP expression was positively correlated with cancer recurrence in a population of breast cancer patients. This suggested that RCP may be required by some tumours for growth and metastatic spread to other organs. When the researchers over-expressed RCP in non-cancerous breast cells, they found that RCP promotes migration, or cellular movement, which is a precursor to the ability of tumours to invade neighbouring tissues. However, breast cancer cells in which RCP is over-expressed take on a more aggressive behaviour, including faster proliferation, enhanced migration/invasion and anchorage-independent growth. The researchers also found that when the gene is silenced in breast cancer cells, the ability of the cells to form tumours and metastasize to other organs is greatly diminished. They also found that RCP can activate the potent oncogene, Ras, which is aberrantly activated by mutation in about 15% of all human cancers. "One objective in my laboratory is to discover new oncogenes that drive breast cancer progression so that we can devise therapeutic strategies for shutting these genes down," said Dr. Miller, now at Wake Forest University School of Medicine in North Carolina. "The involvement of RCP in breast cancer progression may have significant clinical ramifications, and we are now working towards a better understanding of its mechanism of action." Notes: The JCI article is titled, "RCP is a novel breast cancer promoting gene with Ras activating function." Authors: Jinqiu Zhang1,5,9, Xuejing Liu2,9, Arpita Datta2, Kunde Govindarajan3, Wai Leong Tam1, Jianyong Han1, Joshy George3,6, Christopher Wong2, Kalpana Ramnarayanan2, Tze Yoong Phua2, Wan Yee Leong2, Yang Sun Chan2, Nallasivam Palanisamy2,7, Edison Tak-Bun Liu2, Krishna Murthy Karuturi3, Bing Lim1,4,10 and Lance David Miller2,8,10 1 Stem Cell and Developmental Biology, Genome Institute of Singapore, Singapore 2 Cancer Biology and Pharmacology, Genome Institute of Singapore, Singapore 3 Computational and Mathematical Biology, Genome Institute of Singapore, Singapore 4 Center for Life Sciences, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA 5 Current address: Stem Cell Disease Models, Institute of Medical Biology, Singapore 6 Current address: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 7 Current address: Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI, USA 8 Current address: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA 9 These authors contributed equally to this work 10 Corresponding authors: Dr. Lance Miller at Wake Forest University School of Medicine, Winston Salem, NC, Dr. Bing Lim at Genome Institute of Singapore Cathy Yarbrough Agency for Science, Technology and Research (A*STAR), Singapore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):